Which of the following statements is/are correct with reference to the Virafin?
A. Virafin is a pegylated interferon alpha-2b(PegIFN), which when subcutaneously injected to the Covid- 19 patient in the early stages of infection, resulted in their faster recovery.
B. Cadila Healthcare Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat.
C. Both A & B
D. None of these
Explanation:
Drug Controller General of India (DCGI) gave a restricted emergency use approval to the Zydus Cadila’s ‘Virafin’ for treating the patients showing moderate COVID-19 symptoms. Virafin is a pegylated interferon alpha-2b (PegIFN), which when subcutaneously injected to the patient in the early stages of infection, resulted in their faster recovery. Cadila Healthcare Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat.
